What are Recombinant protein vaccine drugs?

Recombinant protein vaccine drugs are pharmacologic agents that share a common mechanism (typically targeting Influenza hemagglutinin). 6 are currently marketed, with 27 more in clinical development.

What are the marketed Recombinant protein vaccine drugs?

Marketed Recombinant protein vaccine drugs include Recombinant influenza hemagglutinin, FluBlok, Meningococcal B (Bexsero), Novavax recombinant protein vaccine, Licensed seasonal influenza vaccine, Licensed 4CMenB vaccine.

Recombinant protein vaccine

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

6 marketed 26 in Phase 3 1 in Phase 2

This page covers all Recombinant protein vaccine drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Influenza hemagglutinin, Influenza hemagglutinin (HA), Meningococcal serogroup B surface antigens (recombinant Neisseria meningitidis proteins).

Targets

Influenza hemagglutinin · Influenza hemagglutinin (HA) · Meningococcal serogroup B surface antigens (recombinant Neisseria meningitidis proteins) · Viral surface antigens (e.g., SARS-CoV-2 spike protein) · Influenza hemagglutinin (HA) protein · Neisseria meningitidis serogroup B surface antigens · SARS-CoV-2 spike protein · SARS-CoV-2 spike protein (original strain and Omicron variant) · Conserved influenza virus epitopes · RSV F glycoprotein (prefusion conformation)

Marketed (6)

Recombinant influenza hemagglutinin · Vaxine Pty Ltd · Immunology / Infectious Disease
Recombinant influenza hemagglutinin stimulates the immune system to produce antibodies and cellular immunity against influenza virus.
FluBlok · The University of Hong Kong · Immunology / Infectious Disease
FluBlok is a recombinant influenza vaccine that stimulates immune response against influenza virus surface antigens.
Meningococcal B (Bexsero) · University of Sao Paulo General Hospital · Immunology / Infectious Disease
Bexsero is a recombinant protein vaccine that stimulates the immune system to produce antibodies against Neisseria meningitidis serogroup B surface antigens.
Novavax recombinant protein vaccine · Henry M. Jackson Foundation for the Advancement of Military Medicine · Immunology / Infectious Disease
A recombinant protein vaccine that presents viral antigens to stimulate adaptive immune responses against infectious pathogens.
Licensed seasonal influenza vaccine · Novavax · Immunology / Infectious Disease
Novavax's seasonal influenza vaccine stimulates the immune system to produce antibodies and cellular immunity against circulating influenza virus strains.
Licensed 4CMenB vaccine · University of Adelaide · Immunology / Infectious Disease
4CMenB is a recombinant meningococcal serogroup B vaccine that stimulates the immune system to produce antibodies against Neisseria meningitidis serogroup B.

Phase 3 pipeline (26)

Clover SCB-2019 · D'Or Institute for Research and Education · Immunology / Infectious Disease
Clover SCB-2019 is a recombinant protein vaccine candidate designed to elicit immune responses against SARS-CoV-2 by presenting stabilized spike protein trimers.
FluBlok Influenza Vaccination · Protein Sciences Corporation · Immunology / Infectious Disease
FluBlok is a recombinant influenza vaccine that stimulates the immune system to produce antibodies against influenza virus surface proteins.
NVX-CoV2373 + NVX-CoV2515 · Novavax · Immunology / Infectious Disease
A bivalent recombinant protein vaccine that stimulates immune responses against both the original SARS-CoV-2 strain and the Omicron variant to prevent COVID-19.
M-001 · BiondVax Pharmaceuticals ltd. · Immunology / Infectious Disease
M-001 is a multivalent recombinant influenza vaccine designed to stimulate broad immune responses against multiple influenza strains.
Meningococcal vaccine GSK134612 · GlaxoSmithKline · Immunology / Infectious Disease
This vaccine stimulates the immune system to produce antibodies against meningococcal serogroup B antigens, providing protection against meningococcal disease.
RSVPreF3 OA vaccine · GlaxoSmithKline · Immunology / Infectious Disease
RSVPreF3 OA is a recombinant protein vaccine that presents a stabilized prefusion form of the respiratory syncytial virus (RSV) F glycoprotein to elicit protective immune responses against RSV infection.
Bexsero® vaccine · ANRS, Emerging Infectious Diseases · Immunology / Infectious Disease
Bexsero is a recombinant meningococcal B vaccine that stimulates the immune system to produce antibodies against Neisseria meningitidis serogroup B.
NVX-CoV2373 + NVX-CoV2540 · Novavax · Immunology / Infectious Disease
A bivalent recombinant protein vaccine that elicits immune responses against both the original SARS-CoV-2 strain and the Omicron variant to prevent COVID-19.
GBP510 adjuvanted with AS03 · SK Bioscience Co., Ltd. · Immunology / Infectious Disease
GBP510 is a recombinant protein subunit vaccine designed to stimulate immune responses against a specific pathogen or disease target, formulated with AS03 adjuvant to enhance immunogenicity.
rLP2086 · Pfizer · Immunology / Infectious Disease
rLP2086 is a recombinant lipoprotein that mimics a naturally occurring lipoprotein to activate the immune system against meningococcal bacteria.
Flublok Quadrivalent vaccine · Tan Tock Seng Hospital · Immunology / Infectious Disease
Flublok Quadrivalent is an inactivated influenza vaccine produced using recombinant DNA technology that stimulates immune response against four strains of influenza virus.
SpikoGen vaccine · Vaxine Pty Ltd · Immunology / Infectious Disease
SpikoGen is a recombinant protein vaccine designed to stimulate immune responses against SARS-CoV-2 spike protein.
NVX-CoV2540 · Novavax · Immunology / Infectious Disease
NVX-CoV2540 is a recombinant protein vaccine that presents the SARS-CoV-2 spike protein to stimulate immune responses against multiple variants of concern.
RSV-F Vaccine · Novavax · Immunology / Infectious Disease
RSV-F Vaccine stimulates the immune system to produce antibodies and cellular immunity against the respiratory syncytial virus fusion (F) protein, preventing RSV infection.
Flublok Quadrivalent Influenza Vaccine · Protein Sciences Corporation · Immunology / Infectious Disease
Flublok Quadrivalent stimulates immune response against four influenza virus strains by presenting recombinant hemagglutinin antigens produced in insect cells.
HPV-16/18 L1/AS04 · GlaxoSmithKline · Oncology / Immunology
This vaccine stimulates the immune system to produce antibodies and cellular immunity against HPV-16 and HPV-18 L1 capsid proteins, preventing infection and cervical cancer development.
SARS-CoV-2 rS antigen/Matrix-M Adjuvant · Novavax · Immunology / Infectious Disease
This vaccine delivers the SARS-CoV-2 spike protein antigen with Matrix-M adjuvant to stimulate immune responses against COVID-19.
Recombinant Mycobacterium Tuberculosis Fusion Protein · Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. · Immunology / Infectious Disease
This recombinant fusion protein combines multiple Mycobacterium tuberculosis antigens to stimulate cellular and humoral immune responses against tuberculosis infection.
RSV F vaccine with adjuvant · Novavax · Immunology / Infectious Disease
This vaccine stimulates the immune system to produce antibodies and cellular immunity against the respiratory syncytial virus (RSV) F protein, preventing RSV infection.
Candidate Plasmodium falciparum malaria vaccine · GlaxoSmithKline · Infectious Disease
This vaccine stimulates the immune system to recognize and attack Plasmodium falciparum parasites, primarily targeting the parasite's pre-erythrocytic and blood-stage antigens to prevent malaria infection and disease.
HBVAXPRO vaccine · Henogen · Immunology / Infectious Disease
HBVAXPRO is a recombinant hepatitis B surface antigen (HBsAg) vaccine that stimulates the immune system to produce antibodies against hepatitis B virus.
SCB-2019/Clover · D'Or Institute for Research and Education · Immunology / Infectious Disease
SCB-2019 is a recombinant protein vaccine candidate designed to stimulate immune responses against SARS-CoV-2 by presenting the spike protein receptor-binding domain.
Malaria Vaccine 257049 · GlaxoSmithKline · Infectious Disease / Immunology
This vaccine stimulates the immune system to recognize and attack Plasmodium parasites that cause malaria by targeting the parasite's pre-erythrocytic and blood-stage antigens.
Bilhvax vaccine (Sh28GST) · Institut National de la Santé Et de la Recherche Médicale, France · Infectious Disease / Parasitology
Bilhvax is a recombinant vaccine targeting schistosome antigens to induce immune responses against Schistosoma haematobium infection.
HPV GSK 580299 vaccine · GlaxoSmithKline · Oncology / Immunology
This vaccine stimulates the immune system to recognize and attack human papillomavirus (HPV)-infected cells by inducing antibodies and T-cell responses against HPV antigens.
LIBP-Rec-Vaccine · National Vaccine and Serum Institute, China · Immunology
LIBP-Rec-Vaccine is a recombinant protein-based vaccine designed to stimulate immune responses against specific disease targets through antigen presentation.

Phase 2 pipeline (1)

Adjuvanted RSVPreF3 vaccine · GlaxoSmithKline · Immunology / Infectious Disease
RSVPreF3 is a recombinant respiratory syncytial virus (RSV) fusion (F) protein vaccine designed to elicit protective immune responses against RSV infection.

Patent intelligence

recombinant protein vaccine patent landscape — aggregated cliff calendar, attackable patents, originator estates